Drug development in dementia
Dementia has only little treatment to control and cure the patient and lots of treatment gone failure. Drug development for the dementia is the tedious one. The first drug was approved in the year 2003 and there is no other approval for the dementia drug development. So the drug development for the dementia is going to be complex.
A new research on dementia is going on using the amyloid, tau and neurodegeneration condition in the national institute of aging. This frame work produces the more stages of dementia. The clinical trials of Dementia are helpful to understanding the roll of the positron emission tomography.
The drug discovery mainly focus on the repurposing of the drugs, which means the drug is already used for many other conditions and this medicine is again used for the dementia with some modification in that chemicals
- Track 1-1 Gantenerumab
- Track 2-2 Solanezumab